Literature DB >> 20471664

Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.

Aron Somorácz1, Péter Tátrai, Gábor Horváth, András Kiss, Péter Kupcsulik, Ilona Kovalszky, Zsuzsa Schaff.   

Abstract

In our earlier work, we demonstrated that agrin, a multifunctional heparan sulfate proteoglycan, accumulates in hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC). In addition, we proved the utility of agrin immumohistochemistry in discriminating between HCCs and benign parenchymal lesions. Here, we have examined the expression of agrin in metastatic liver carcinomas in comparison with primary liver tumors. Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods. Agrin/CD34 double immunofluorescent staining was carried out on snap-frozen sections. Agrin mRNA expression was measured in 11 HCC, 7 CCC, 11 CRCm, and 12 normal liver tissues. Regardless of tumor grade, agrin immunostaining was strong in the microvessels of HCCs. As opposed to HCC, agrin immunostaining was faint or nearly absent from the CD34-positive microvessels of CCC, CRCm, and PDCm; rather, it was detected in the basement membranes surrounding tumor cell pseudoglandules. While agrin was preserved in the basement membranes of Grade III CCCs, it was nearly absent from poorly differentiated metastatic adenocarcinomas. Agrin mRNA levels were the highest in CCC and lower, but still elevated in HCC and CRCm. By qualitative evaluation of agrin immunoreactions, CCC was differentiated from CRCm and PDCm with a sensitivity of 0.81 and a specificity of 0.82. HCCs were unequivocally identified on the basis of microvascular agrin labeling. Thus, agrin immunohistochemistry may facilitate determination of primary versus metastatic origin in problematic liver cancer cases. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471664     DOI: 10.1016/j.humpath.2009.10.029

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma.

Authors:  Jody E Hooper; Terry K Morgan; Markus Grompe; Brett C Sheppard; Megan L Troxell; Christopher L Corless; Philip R Streeter
Journal:  Hum Pathol       Date:  2012-03-09       Impact factor: 3.466

2.  Expression of Tight Junction Components in Hepatocyte-Like Cells Differentiated from Human Embryonic Stem Cells.

Authors:  Boglárka Erdélyi-Belle; György Török; Ágota Apáti; Balázs Sarkadi; Zsuzsa Schaff; András Kiss; László Homolya
Journal:  Pathol Oncol Res       Date:  2015-04-07       Impact factor: 3.201

Review 3.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.

Authors:  Julia Kälsch; Juliet Padden; Stefanie Bertram; Leona L Pott; Henning Reis; Daniela Westerwick; Christoph M Schaefer; Jan-P Sowa; Dorothe Möllmann; Christian Fingas; Alexander Dechȇne; Barbara Sitek; Martin Eisenacher; Ali Canbay; Maike Ahrens; Hideo A Baba
Journal:  Virchows Arch       Date:  2017-03-29       Impact factor: 4.064

5.  MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree.

Authors:  Christine Bollwein; Juliana Pereira Lopes Gonҫalves; Kirsten Utpatel; Wilko Weichert; Kristina Schwamborn
Journal:  Molecules       Date:  2022-05-27       Impact factor: 4.927

6.  Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.

Authors:  Juliet Padden; Maike Ahrens; Julia Kälsch; Stefanie Bertram; Dominik A Megger; Thilo Bracht; Martin Eisenacher; Peri Kocabayoglu; Helmut E Meyer; Bence Sipos; Hideo A Baba; Barbara Sitek
Journal:  Mol Cell Proteomics       Date:  2015-12-07       Impact factor: 5.911

7.  An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma.

Authors:  Sayan Chakraborty; Manikandan Lakshmanan; Hannah L F Swa; Jianxiang Chen; Xiaoqian Zhang; Yan Shan Ong; Li Shen Loo; Semih Can Akıncılar; Jayantha Gunaratne; Vinay Tergaonkar; Kam M Hui; Wanjin Hong
Journal:  Nat Commun       Date:  2015-01-29       Impact factor: 14.919

8.  Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma.

Authors:  Rebeca Kawahara; Daniela C Granato; Carolina M Carnielli; Nilva K Cervigne; Carine E Oliveria; César Rivera; César A R Martinez; Sami Yokoo; Felipe P Fonseca; Marcio Lopes; Alan R Santos-Silva; Edgard Graner; Ricardo D Coletta; Adriana Franco Paes Leme
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

9.  Agrin has a pathological role in the progression of oral cancer.

Authors:  César Rivera; Flávia Silva Zandonadi; Celeste Sánchez-Romero; Ciro Dantas Soares; Daniela Campos Granato; Wilfredo Alejandro González-Arriagada; Adriana Franco Paes Leme
Journal:  Br J Cancer       Date:  2018-06-06       Impact factor: 7.640

Review 10.  Heparan Sulfate Proteoglycans May Promote or Inhibit Cancer Progression by Interacting with Integrins and Affecting Cell Migration.

Authors:  Mariana A Soares; Felipe C O B Teixeira; Miguel Fontes; Ana Lúcia Arêas; Marcelo G Leal; Mauro S G Pavão; Mariana P Stelling
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.